Literature DB >> 29444500

Generation of induced pluripotent stem cell line (ZZUi004-A) from urine sample of a patient with spinocerebellar ataxia type 3.

Yanlin Wang1, Changhe Shi1, Zhilei Wang1, Huifang Sun1, Zhihua Yang1, Fan Zhang2, Yutao Liu1, Han Liu1, Chenyang Jiang1, Shoutao Zhang3, Yuming Xu4, Xuejun Wen5.   

Abstract

Spinocerebellar ataxia type 3 (SCA3) is a dominantly inherited neurodegenerative disease caused by a CAG repeat expansion in the region of the ATXN3 gene. The main feature of SCA3 is progressive ataxia, which affects balance, gait, and speech. Urine cells (UCs) of a SCA3 patient were successfully translated to induced pluripotent stem cells (iPSCs) by using the Sendai virus delivery system. ZZUi004-A cell line may provide a robust platform for further study of SCA3 pathogenesis as well as drug testing and gene therapy research.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2018        PMID: 29444500     DOI: 10.1016/j.scr.2018.01.027

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  3 in total

1.  Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line.

Authors:  Lauren R Moore; Laura Keller; David D Bushart; Rodrigo G Delatorre; Duojia Li; Hayley S McLoughlin; Maria do Carmo Costa; Vikram G Shakkottai; Gary D Smith; Henry L Paulson
Journal:  Stem Cell Res       Date:  2019-07-16       Impact factor: 2.020

Review 2.  Urinary Stem Cells as Tools to Study Genetic Disease: Overview of the Literature.

Authors:  Maria Sofia Falzarano; Alessandra Ferlini
Journal:  J Clin Med       Date:  2019-05-08       Impact factor: 4.241

Review 3.  Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias.

Authors:  Bart P C van de Warrenburg; Hans van Bokhoven; Marina P Hommersom; Ronald A M Buijsen; Willeke M C van Roon-Mom
Journal:  Stem Cell Rev Rep       Date:  2021-05-25       Impact factor: 5.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.